# Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

> **NCT02991196** · PHASE1 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Neoplasm

## Interventions

- **DRUG:** DS-8273a + nivolumab

## Key facts

- **NCT ID:** NCT02991196
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2017-09-22
- **Final completion:** 2017-09-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2019-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991196, "Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02991196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*